*ST京蓝(000711) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥13,988,688.02, a decrease of 75.65% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥117,656,352.88, representing a 32.40% increase in losses year-over-year[5]. - The basic and diluted earnings per share were both -¥0.1149, a decrease of 32.41% compared to the previous year[5]. - Total revenue for Q3 2023 was CNY 116,018,879.39, a decrease of 36.1% compared to CNY 181,468,017.97 in the same period last year[22]. - Net loss for Q3 2023 was CNY 906,921,595.82, compared to a net loss of CNY 483,406,747.69 in Q3 2022, representing an increase in loss of 87.7%[23]. - The net profit attributable to the parent company for Q3 2023 was -761,596,633.55 CNY, compared to -434,453,658.34 CNY in the same period last year, indicating a significant increase in losses[24]. - The total comprehensive income for the parent company in Q3 2023 was -843,415,525.38 CNY, up from -434,453,658.34 CNY year-over-year[24]. - The basic and diluted earnings per share for Q3 2023 were both -0.7440 CNY, compared to -0.42 CNY in Q3 2022[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,693,104,015.31, down 10.36% from the end of the previous year[5]. - Total assets decreased to CNY 6,693,104,015.31 from CNY 7,466,340,011.39, a decline of 10.3%[20]. - Total liabilities increased to CNY 8,314,738,711.96 from CNY 8,099,234,220.39, an increase of 2.7%[20]. - The company’s total equity decreased to CNY -1,621,634,696.65 from CNY -632,894,209.00, indicating a worsening financial position[20]. Cash Flow - The cash flow from operating activities showed a net amount of ¥397,637.82, a significant decrease of 99.09% compared to the same period last year[9]. - Cash inflows from operating activities totaled 376,023,587.20 CNY, down from 438,609,643.76 CNY in the previous year[26]. - The net cash flow from operating activities was 397,637.82 CNY, a decrease from 43,885,135.90 CNY in the same period last year[26]. - The net cash flow from investing activities was -18,601,254.54 CNY, compared to 5,817,618.73 CNY in the previous year, indicating a decline in investment returns[26]. - The net cash flow from financing activities was -10,050,861.30 CNY, worsening from -78,069,401.75 CNY year-over-year[26]. - The ending balance of cash and cash equivalents was 15,323,507.42 CNY, compared to 11,384,424.45 CNY at the end of Q3 2022[27]. - The company reported a decrease in cash received from sales of goods and services, totaling 309,905,541.99 CNY, down from 383,239,022.10 CNY in the previous year[25]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,834[11]. - The top shareholder, Beijing Yangshu Lantian Investment Center, holds 16.68% of the shares, amounting to 170,763,781 shares[11]. Impairments and Restructuring - The company reported a credit impairment loss of -¥116,362,599.73, an increase of 201.56% year-over-year due to receivables impairment[9]. - The company is undergoing a restructuring process initiated by creditors due to its inability to repay debts, with the first creditors' meeting held on July 20, 2023[15]. - The company reported a negative net asset value as of December 31, 2022, leading to a risk warning for delisting from the Shenzhen Stock Exchange[14]. Asset Disposals - The company has publicly auctioned a 2.9171% stake in Baotou Rural Commercial Bank, with a transaction price of RMB 4,412,800 on October 3-4, 2023[16]. - A 90.11179% stake in Jinglan North Garden (Tianjin) Co., Ltd. was auctioned for RMB 11,900,001 on October 13-14, 2023, which will affect the company's consolidated financial statements[17]. - The company is in the process of disposing of certain equity and receivable assets, with the impact on financial statements to be determined after auditing[18]. Research and Development - Research and development expenses for the first nine months of 2023 were ¥9,624,634.15, a reduction of 52.95% compared to the same period in 2022[9].